Smarter PATH™ · Patent Pending
Welcome to Smarter PATH™
Purpose-built and driven regulatory intelligence for drug developers, point of care service providers, Private Equity and Venture Capital investors navigating complex approval landscapes.
The Framework
Three lenses. One continuous system.
The three suites overlap on purpose. Each one hands the next a complete picture, so no decision is made without the context the others already established.
First investor dollar
Last post-market commitment
Suite 01
Smarter PATH™ to Approval
Guides development programs from IND to BLA with the continuous, stage-specific regulatory strategy that transforms promising science into successful submissions.
IND→
Phase 1→
Phase 2→
Phase 3→
BLA
Suite 02
Smarter PATH™ to Investing
Gives PE and VC investors the regulatory lens that financial diligence does not provide: an independent assessment of approval probability, CMC and manufacturing readiness, exclusivity architecture, and the specific gaps that separate a program worth funding from one that is carrying a CRL it doesn't yet know about.
Approval Probability
CMC & Manufacturing Readiness
Exclusivity Architecture
Gap Identification
Suite 03
Smarter PATH™ to Risk Management
Designs post-approval safety programs as evidence-generating, access-maximizing infrastructure.
So that approval is the beginning of patient access, not another obstacle delaying patient care.
One System
A powerful, three-pronged framework that forms a single, continuous regulatory intelligence system: from the first investor dollar to the last post-market commitment, Smarter PATH™ ensures that the decisions that determine regulatory outcomes are made with the full picture, allowing the intelligence to forge the path.
